CytomX Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
CytomX Therapeutics (CTMX) Reports In-Line Q2 EPS
August 4, 2022 5:21 PM EDTCytomX Therapeutics (NASDAQ: CTMX) reported Q2 EPS of ($0.37), in-line with the analyst estimate of ($0.37). Revenue for the quarter came in at $18.17 million versus the consensus estimate of $18.11 million.
For earnings history and earnings-related data on CytomX Therapeutics (CTMX) click here.
... More